Ligand Pharmaceuticals Incorporated director Jason M. Aryeh filed a Form 144 notice on October 30, 2026, disclosing a proposed sale of 1,209 shares of common stock on NASDAQ.

Key Highlights

  • Seller: Jason M. Aryeh, a director of Ligand Pharmaceuticals Incorporated
  • Shares proposed for sale: 1,209 shares of common stock
  • Aggregate market value: $385,185.47
  • Broker named: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004
  • Approximate date of sale: October 30, 2026
  • Original acquisition: 1,209 shares acquired on June 5, 2026, as restricted stock from the issuer
  • Shares outstanding: 19,935,609 shares of common stock reported outstanding

Details of Jason Aryeh's Proposed Share Sale at Ligand Pharmaceuticals

According to the Form 144 filing, Jason M. Aryeh, identified as a director of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), submitted a notice of proposed sale of securities on October 30, 2026. The filing discloses that Aryeh intends to sell 1,209 shares of the company's common stock, with an aggregate market value listed as $385,185.47. The proposed transaction is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services.

The filing states that the 1,209 shares to be sold were acquired on June 5, 2026, through a restricted stock transaction from the issuer, with the date of payment also listed as June 5, 2026, and the nature of payment recorded as "Not Applicable." The filing notes no securities of Ligand Pharmaceuticals were sold by Aryeh during the past three months, listing that section as "Nothing to Report." The issuer's address is listed as 555 Heritage Drive, Suite 200, Jupiter, Florida 33458.

By signing the notice, the filing states that Aryeh "represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed." The total shares outstanding of Ligand Pharmaceuticals common stock are reported in the filing as 19,935,609.

What Was Disclosed

Director Jason M. Aryeh filed a Form 144 notice proposing the sale of 1,209 restricted shares of Ligand Pharmaceuticals common stock, with an aggregate market value of $385,185.47, acquired June 5, 2026, with the proposed sale dated October 30, 2026.